OncoQR ML offers different partnering opportunities, both on technology and product level:

Its proprietary STIR-Platformis available for licensing on a target-by-target basis. With its scientifically validated proof of concept, it offers the chance to rapidly develop new vaccines from to design to Proof of Concept within 9 to 12 months. The lead candidate OQR200 is available for licensing: It triggers an active, reversible and appropriate immune response without side effects. A pre-clinical information package will be made available under CDA. Further data will be available as of end July, 2017.

The lead candidate TYG100 is also available for licensing through TYG-oncology Ltd.

Download Non-confidential Information Folder here

Download Non-confidential Company Presentation here